Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04650126




Registration number
NCT04650126
Ethics application status
Date submitted
5/11/2020
Date registered
2/12/2020
Date last updated
21/07/2022

Titles & IDs
Public title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers
Scientific title
A Phase I, Randomized, Double-blind, Parallel Group and Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab in Response to Single Ascending Intravenous Infusion Doses.
Secondary ID [1] 0 0
ATM001-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - ATM001
Treatment: Other - ATM001 Placebo

Experimental: ATM001 - Escalating dose levels of ATM001 administered as single dose in healthy subjects

Placebo comparator: ATM001 Placebo - Escalating dose levels of ATM001 Placebo administered as single dose in healthy subjects


Treatment: Other: ATM001
monovalent anti-TNF-receptor 1 antibody format

Treatment: Other: ATM001 Placebo
ATM001 Placebo
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
pharmacokinetic (PK): Area under the analyte concentration-time curve from time 0 and extrapolated to infinite time (AUC 0-8)
Timepoint [1] 0 0
8 days
Primary outcome [2] 0 0
PK: Area under the plasma concentration curve from administration until the last quantifiable sampling point (AUC 0-t)
Timepoint [2] 0 0
8 days
Primary outcome [3] 0 0
PK: Maximum Plasma Concentration [Cmax]
Timepoint [3] 0 0
8 days
Primary outcome [4] 0 0
PK: Terminal half life (t1/2)
Timepoint [4] 0 0
8 days
Primary outcome [5] 0 0
PK: Apparent terminal elimination rate constant (?z)
Timepoint [5] 0 0
8 days
Primary outcome [6] 0 0
PK: Mean residence time (MRT)
Timepoint [6] 0 0
8 days
Primary outcome [7] 0 0
PK: Clearance (CL)
Timepoint [7] 0 0
8 days
Primary outcome [8] 0 0
PK: Apparent volume of distribution (Vz)
Timepoint [8] 0 0
8 days
Primary outcome [9] 0 0
Any adverse event, serious adverse event (SAE)
Timepoint [9] 0 0
4 weeks

Eligibility
Key inclusion criteria
* healthy male subjects
* body mass index 18-32 kg/m2
* normal physical examination, clinical laboratory values and ECG
* additional inclusion criteria apply
Minimum age
18 Years
Maximum age
55 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
* febrile or infectious illness at least 7 days prior to the first administration
* any active physical disease, acute or chronic
* history of alcohol or drug abuse
* history of chronic or recurrent metabolic, renal, hepatic, pulmonary, gastrointestinal, neurological, endocrinological, immunological, psychiatric, or cardio-vascular disease, myopathies and bleeding tendency
* additional exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/07/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/03/2022
Sample size
Target
Accrual to date
Final
42
Recruitment in Australia
Recruitment state(s)
Brisban
Recruitment hospital [1] 0 0
Q-Pharm - Herston
Recruitment postcode(s) [1] 0 0
4006 - Herston

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Baliopharm Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Kristi McLendon, MD
Address 0 0
Q-Pharm Pty Limited
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT04650126